Stem cell therapy improves condition of patients with type 2 diabetes

06/19/2014 | Australian Life Scientist

Type 2 diabetes patients who were treated with infusions of Mesoblast's mesenchymal precursor cells had greater reductions in blood sugar levels than those who received a placebo, according to a study presented at a meeting of the American Diabetes Association. The 61-patient midstage trial found that the cells were well-tolerated and that treatment was associated with a dose-dependent improvement in glycemic control.

View Full Article in:

Australian Life Scientist

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ